SavedAdd your journal

Journals / Kocatepe Tıp Dergisi / 2011 / Cilt: 12 Sayı: 3

Jinekolojik Onkolojide Tümör Belirteçleri: Literatür Derleme

İbrahim Alanbay
Hakan Çoksüer
Cihangir Mutlu Ercan
Pages
157–163
Publication Date
2011-12-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu derlemede jinekolojik kanserlerde tümör belirteçlerinin rolü tartışılmıştır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Jinekolojik kanserler; ovaryan, servikal, endometriyal, vulvar kanserler olup kadınlardaki yıllık 5,1 milyon yeni kanserin %19’unu oluşturmaktadır.
📊
Key Findings & Data:Serum tümör belirteçleri hastalığın taramasında, tespit edilmesinde, tedavinin monitorizasyonunda ve takip programında, özellikle rekürrensin prediksiyonunda önemli rol oynamaktadır.
💡
Conclusion & Impact:Bu derlemede jinekolojik kanserlerde tümör belirteçlerinin rolü tartışılmıştır.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Jinekolojik kanserler · tümör belirteçleri · tanı

Özet

Jinekolojik kanserler; ovaryan, servikal, endometriyal, vulvar kanserler olup kadınlardaki yıllık 5,1 milyon yeni kanserin %19’unu oluşturmaktadır. Serum tümör belirteçleri hastalığın taramasında, tespit edilmesinde, tedavinin monitorizasyonunda ve takip programında, özellikle rekürrensin prediksiyonunda önemli rol oynamaktadır. Bu derlemede jinekolojik kanserlerde tümör belirteçlerinin rolü tartışılmıştır.

🔖

Cite This Article

Alanbay, İ., Çoksüer, H., Ercan, C. M. (2011). Jinekolojik Onkolojide Tümör Belirteçleri: Literatür Derleme. Kocatepe Tıp Dergisi, Cilt: 12 Sayı: 3, 157–163. https://doi.org/10.18229/ktd.06939

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (39)

  1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer; the size of the problem. Bailliere’s Best Pract Res. 2006; 20: 207-225
  2. Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010; 67:46-53.
  3. American Cancer Society Cancer Facts & Figures 2009 Atlanta: American Cancer Society. 2009;1:1-68. 4. Richard G. Moore, Shannon MacLaughlan, Robert C. Bast Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology. 2010;116: 240–245
  4. Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic epitheliumrelated antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–285.
  5. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, et al. The concomitant determination of different tümör markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44: 147– 154.
  6. İbrahim Alanbay, Emre Karaşahin, Mutlu Ercan, Ulaş Fidan, Murat Dede, Mufit C. Yenen. Rüptüre Endometriyoma ve yüksek serum tümor belirteçleri; olgu sunumu. Gülhane Tıp Dergisi. 2010; 52: 49- 51
  7. Gadducci A, Zola P, Landoni F, et al. Serum half- life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric 1995;58:42–47 study. Gynecol
  8. Oncol. 9. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et al.Elevation of multiple serum markers in patients with stage I ovarian cancer.J Natl Cancer Inst. 1993;85:1748-1751
  9. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol. 2010;136(7):1079- 1088
  10. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009;113:384–394.
  11. Brown AK, Miller MC, Robison K, et al. Differential expression of CA125 and a novel serum tümör marker HE4 in epithelial ovarian cancer. J Clin Oncol. 2009;26: 20-23.
  12. Gadducci A, Sartori E, Zola P, et al. Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer: a CTF study. Oncol Rep. 1996;3:301–303.
  13. Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000; 15:147–152
  14. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Fanucchi A. The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study. Gynecol Oncol. 1996; 63: 234–237
  15. van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA 125 and TPS levels after three chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444–450.
  16. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28:2159-2166.
  17. M. Dede, S. Gungor, M.C. Yenen, I. Alanbay, N.K. Duru, A. Haşimi. Ca19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer. 2006;16: 189- 193
  18. Kawai M, Furuhashi Y, Kano K, et al. Alphafetoprotein in malignant germ cell tümörs of the ovary. Gynecol Oncol. 1990;39:160–166.
  19. International Germ Cell Consensus Classification: a prognostic factorbased staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594–603
  20. Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tümörs: identification of novel prognostic markers and longterm outcome after multimodality treatment. J Clin Oncol. 2006;24:4862– 4866
  21. Rey RA, Lhomme C, Marcillac I, et al. Antimullerian hormone as a serum marker of granulosa cell tümörs of the ovary: comparative study with serum alpha inhibin and estradiol. Am J Obstet Gynecol. 1996;174:958–965.
  22. Zhordania KI, Kerzhkovskaia NS, Lyubimova NV. Using inhibin-A to monitor granulosa cell tümör of the ovary. Int J Gynecol Cancer. 2003;13:45-47.
  23. Fuller AF, Kehas DJ, Donahoe PK, MacLaughlin DK. Diagnostic utility of mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tümörs. Gynecol Oncol. 1999; 73:51–55.
  24. Yoon SM, Shin KH, Kim JY, et al. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy. Int J Gynecol Cancer. 2007;17: 872–878.
  25. Ngan HY, Cheung AN, Lauder IJ, Wong LC, Ma HK. Prognostic significance of serum tumour markers in carcinoma of the cervix. Eur J Gynaecol Oncol. 1996;17:512–517.
  26. Straussa H-G, Labana C, Lautenschla C, Buchmannc J, Schneiderd I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer. 2002;38:1987–1989
  27. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R,Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000;20:5113–5115.
  28. Kainz C, Sliutz G, Mustafa G, et al. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow- up of cervical cancer. Gynecol Oncol. 1995;56:402– 405.
  29. Tsai SC, Kao CH, Wang SJ. Study of a new tümör marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Neoplasma. 1996;43:27–29.
  30. Mathur P, Mathur RS, Gray EA, et al. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B. Gynecol Oncol. 2005;98:467–483
  31. Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S. CA 15-3 as a tümör marker in gynecological malignancies. Gynecol Oncol. 1988; 30: 265–273.
  32. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005;50:585–590
  33. Dotters DJ preoperative CA 125 in endometrial cancer, is it useful Am J Obstet Gynecol. 2000;182: 1328-1334
  34. Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tümör biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196–201
  35. Hefler A, Sliutz G, Leodolter S, et al. Squamous cell carcinoma antigen serum levels as prognostic parameter in patients with early stage vulvar cancer. Gynecol Oncol. 2005;97:904–907.
  36. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4:670-678. 38. Cole LA, Dai D, Butler SA, Leslic KK, Kohorn EI. GestationaL trophobastic diseases1: pathophy- siology of hyperglycosylated HCG. Gynecol Oncol. 2006; 102; 145-150.
  37. Kelly LS, Birken S, Puett D. Determination of hyperglycosylated human chorionic gonodotropin produced by malignant gestational trophoblastic neoplasia and male germ cell tümörs using a lectin- based immunoassay and surface plasmon resonance moll coll Endocrinol. 2007; 2: 33-39
  38. Berkowitz RS, Goldstein DP, DuBeshter B, Bernstein MR, Management of complete molar pregnancy. J Reprod Med. 1987;32:634-639
  39. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer. 2001;11:73-77.